Adoptive immunotherapy with macrophage activated killer (MAK) cells appears to be a safe treatment for superficial bladder cancer that can reduce the risk of recurrence following resection, according to a recent report.
Dr. Nicolas Thiounn, from Hopital Cochin in Paris, and colleagues assessed the outcomes of 17 patients with TaGIII or TaGII superficial bladder cancer who were treated with autologous MAK cells following transurethral tumor resection.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!